Please assess the completion status of the following clinical trial:

Trial Title: Phase 2 Dose-finding Study to Evaluate the Effects of BA058 in the Treatment of Postmenopausal Women With Osteoporosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 5.0

Eligibility Criteria:
Primary Inclusion Criteria:~* The patient has a bone mineral density T-score ≤ 2.5 at the lumbar spine or hip (femoral neck) by dual energy x-ray absorptiometry (DXA). Women with a bone mineral density T-score of 2.0 or lower and a prior low-trauma forearm, humerus, vertebral, sacral, pelvic, hip, femoral, or tibial fracture within the past 5 years, or who have an additional risk factor such as age 65 or greater or a strong maternal history of osteoporosis defined as a fracture related to osteoporosis or osteoporosis itself as determined by BMD criteria, are also study candidates.~* The patient is in good general health as determined by medical history and physical examination and is without evidence of clinically significant abnormality in the opinion of the Investigator.~Primary Exclusion Criteria:~* History of bone disorders (e.g., Paget's disease) other than postmenopausal osteoporosis.~* Prior treatment with approved or as yet unapproved bone-acting investigational agents.~* History of carcinoma, nephrolithiasis or urolithiasis within the past five years or osteosarcoma at any time.~* History of radiotherapy (radiation therapy).

- Gender: FEMALE
- Minimum Age: 55 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): None
- BA058 20 µg (Type: EXPERIMENTAL): None
- BA058 40 µg (Type: EXPERIMENTAL): None
- BA058 80 µg (Type: EXPERIMENTAL): None
- teriparatide (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).